{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T18:13:39Z","timestamp":1783620819916,"version":"3.55.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T00:00:00Z","timestamp":1734048000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T00:00:00Z","timestamp":1734048000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","award":["CAN 2018\/664"],"award-info":[{"award-number":["CAN 2018\/664"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["ALFGBG-7229219"],"award-info":[{"award-number":["ALFGBG-7229219"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005760","name":"University of Gothenburg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005760","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Surg Endosc"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>In biliary cancer, the indication of endoscopic intervention might be diagnostic as well as therapeutic, in the latter situation with the aim to relieve biliary obstruction e.g. by stenting. Our aim was to investigate the use of endoscopic biliary interventions during the diagnostic workup of biliary cancers in a national cohort, and to evaluate their complications, especially cholangitis and pancreatitis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This is a registry-based study of national cohort of patients with biliary cancers in Sweden 2010\u20132020. The use of endoscopic retrograde cholangiopancreatography (ERCP) during the diagnostic work up period before treatment onset, and risk of complications were evaluated in patients with gallbladder cancer, intrahepatic-, perihilar- and distal cholangiocarcinoma. The risk of complications was compared depending on age, sex, comorbidity, in relation to stage and curative intent, endoscopy unit size, and with relation to survival.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Forty percent of the patients with biliary cancer underwent ERCP during the diagnostic workup, with variations depending on diagnosis. There was a 20% overall risk of periprocedural complications, a 9% risk of post-ERCP-pancreatitis (PEP), and a 6% risk of cholangitis. Increasing tumor stage did not increase risk, nor did comorbidity. The complication rates were slightly higher for younger patients and those undergoing curative treatment. For perihilar cholangiocarcinoma (pCCA) treated with curative intention, the risk of periprocedural complications was as high as 30.7%. No association between post-ERCP complications and survival was found.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Irrespective of type of biliary cancer, ERCP is frequently used during diagnostic workup. The complication risk indicates that primary biliary cancers are complication prone, regardless of stage. Notably the risk of complications was the highest for younger patients with low comorbidity scores, as well as for patients undergoing curatively aiming treatment.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00464-024-11449-8","type":"journal-article","created":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T16:11:37Z","timestamp":1734106297000},"page":"991-1001","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Risks and use of ERCP during the diagnostic workup in a national cohort of biliary cancer"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-5296-9435","authenticated-orcid":false,"given":"Anna","family":"Forslund","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Haraldsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Holmberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Naredi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus","family":"Rizell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,13]]},"reference":[{"key":"11449_CR1","unstructured":"GallRiks (2023) \u00c5rsrapport 2022 Nationellt kvalitetsregister f\u00f6r gallstenskirurgi och ERCP. https:\/\/www.ucr.uu.se\/gallriks\/for-vardgivare\/rapporter\/arsrapporter\/arsrapport-2022\/viewdocument\/987"},{"key":"11449_CR2","doi-asserted-by":"publisher","unstructured":"Dumonceau J-M, Kapral C, Aabakken L et al (2020) ERCP-related adverse events: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 52(2):127\u2013149. https:\/\/doi.org\/10.1055\/A-1075-4080","DOI":"10.1055\/A-1075-4080"},{"issue":"10","key":"11449_CR3","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1055\/s-2003-42614","volume":"35","author":"E Masci","year":"2003","unstructured":"Masci E, Mariani A, Curioni S, Testoni PA (2003) Risk factors for pancreatitis following endoscopic retrograde cholangiopancreatography: a meta-analysis. Endoscopy 35(10):830\u2013834. https:\/\/doi.org\/10.1055\/s-2003-42614","journal-title":"Endoscopy"},{"key":"11449_CR4","doi-asserted-by":"publisher","unstructured":"Tierney J, Bhutiani N, Stamp B, Richey JS, Bahr MH, Vitale GC (2018) Predictive risk factors associated with cholangitis following ERCP. Surg Endosc 32(2):799\u2013804. https:\/\/doi.org\/10.1007\/S00464-017-5746-Z","DOI":"10.1007\/S00464-017-5746-Z"},{"issue":"10272","key":"11449_CR5","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","volume":"397","author":"JW Valle","year":"2021","unstructured":"Valle JW, Kelley RK, Nervi B, Oh DY, Zhu AX (2021) Biliary tract cancer. The Lancet 397(10272):428\u2013444. https:\/\/doi.org\/10.1016\/S0140-6736(21)00153-7","journal-title":"The Lancet"},{"issue":"3","key":"11449_CR6","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1007\/s12029-020-00390-3","volume":"51","author":"B Moazzami","year":"2020","unstructured":"Moazzami B, Majidzadeh-A K, Dooghaie-Moghadam A et al (2020) Cholangiocarcinoma: state of the art. J Gastrointest Cancer 51(3):774\u2013781. https:\/\/doi.org\/10.1007\/s12029-020-00390-3","journal-title":"J Gastrointest Cancer"},{"issue":"5","key":"11449_CR7","doi-asserted-by":"publisher","first-page":"2660","DOI":"10.1245\/s10434-021-09671-y","volume":"28","author":"ZV Fong","year":"2021","unstructured":"Fong ZV, Brownlee SA, Qadan M, Tanabe KK (2021) The clinical management of cholangiocarcinoma in the united states and Europe: a comprehensive and evidence-based comparison of guidelines. Ann Surg Oncol 28(5):2660\u20132674. https:\/\/doi.org\/10.1245\/s10434-021-09671-y","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"11449_CR8","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1016\/j.jhep.2022.07.022","volume":"77","author":"M Vithayathil","year":"2022","unstructured":"Vithayathil M, Khan SA (2022) Current epidemiology of cholangiocarcinoma in Western countries. J Hepatol 77(6):1690\u20131698. https:\/\/doi.org\/10.1016\/j.jhep.2022.07.022","journal-title":"J Hepatol"},{"issue":"3","key":"11449_CR9","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.cld.2020.04.005","volume":"24","author":"AP Buckholz","year":"2020","unstructured":"Buckholz AP, Brown RS (2020) Cholangiocarcinoma: diagnosis and management. Clin Liver Dis 24(3):421\u2013436. https:\/\/doi.org\/10.1016\/j.cld.2020.04.005","journal-title":"Clin Liver Dis"},{"key":"11449_CR10","unstructured":"Regionala Cancercentrum i Samverkan (n.d.) Svenska registret f\u00f6r cancer i lever, gallbl\u00e5sa och gallv\u00e4gar (SweLiv) - RCC. https:\/\/cancercentrum.se\/samverkan\/cancerdiagnoser\/lever-och-galla\/kvalitetsregister\/. Accessed December 10, 2023"},{"key":"11449_CR11","unstructured":"Regionala Cancercentrum i Samverkan (n.d.) Nationellt kvalitetsregister f\u00f6r bukspottk\u00f6rtelcancer (pankreasregistret) - RCC. https:\/\/cancercentrum.se\/samverkan\/cancerdiagnoser\/bukspottkortel\/kvalitetsregister\/. Accessed December 10, 2023"},{"key":"11449_CR12","unstructured":"Regionalt Cancercentrum V\u00e4st (2021) Cancer i Lever Och Gallv\u00e4gar, SweLiv. www.rccvast.se. Accessed August 29, 2022"},{"key":"11449_CR13","unstructured":"Regionala Cancercentrum i Samverkan (2021) Kvalitetsregister F\u00f6r Tum\u00f6rer i Pankreas Och Periampull\u00e4rt \u00c5rsrapport Nationellt Kvalitetsregister."},{"key":"11449_CR14","unstructured":"GallRiks (n.d.) F\u00f6rstasidan. https:\/\/www.ucr.uu.se\/gallriks\/. Accessed December 10, 2023"},{"key":"11449_CR15","unstructured":"GallRiks (2021) \u00c5rsrapport 2020 Nationellt Kvalitetsregister F\u00f6r Gallstenskirurgi Och ERCP"},{"issue":"5","key":"11449_CR16","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1001\/jamasurg.2013.1221","volume":"148","author":"L Enochsson","year":"2013","unstructured":"Enochsson L, Thulin A, \u00d6sterberg J, Sandblom G, Persson G (2013) The Swedish registry of gallstone surgery and endoscopic retrograde cholangiopancreatography (GallRiks): a nationwide registry for quality assurance of gallstone surgery. JAMA Surg 148(5):471\u2013478. https:\/\/doi.org\/10.1001\/jamasurg.2013.1221","journal-title":"JAMA Surg"},{"issue":"4","key":"11449_CR17","doi-asserted-by":"publisher","first-page":"347","DOI":"10.20524\/aog.2023.0810","volume":"36","author":"J Dhar","year":"2023","unstructured":"Dhar J, Gupta P, Samanta J (2023) The role of endoscopy in malignant hilar obstruction. Ann Gastroenterol 36(4):347\u2013359. https:\/\/doi.org\/10.20524\/aog.2023.0810","journal-title":"Ann Gastroenterol"},{"issue":"3","key":"11449_CR18","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.giec.2022.01.003","volume":"32","author":"TH Lee","year":"2022","unstructured":"Lee TH, Moon JH, Stuart S (2022) Role of ERCP in malignant hilar biliary obstruction. Gastrointest Endosc Clin N Am 32(3):427\u2013453. https:\/\/doi.org\/10.1016\/j.giec.2022.01.003","journal-title":"Gastrointest Endosc Clin N Am"},{"issue":"3","key":"11449_CR19","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1080\/00365521.2023.2282375","volume":"59","author":"IM Mikalsen","year":"2024","unstructured":"Mikalsen IM, Breder S, Medhus AW, Folseraas T, Aabakken L, \u00c5nonsen KV (2024) ERCP for the initial management of malignant biliary obstruction\u2013real world data on 596 procedures. Scand J Gastroenterol 59(3):369\u2013377. https:\/\/doi.org\/10.1080\/00365521.2023.2282375","journal-title":"Scand J Gastroenterol"},{"issue":"10035","key":"11449_CR20","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1016\/S0140-6736(16)30310-5","volume":"387","author":"H Luo","year":"2016","unstructured":"Luo H, Zhao L, Leung J et al (2016) Routine pre-procedural rectal indometacin versus selective post-procedural rectal indometacin to prevent pancreatitis in patients undergoing endoscopic retrograde cholangiopancreatography: a multicentre, single-blinded, randomised controlled trial. The Lancet 387(10035):2293. https:\/\/doi.org\/10.1016\/S0140-6736(16)30310-5","journal-title":"The Lancet"},{"issue":"10425","key":"11449_CR21","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/S0140-6736(23)02356-5","volume":"403","author":"BJ Elmunzer","year":"2024","unstructured":"Elmunzer BJ, Foster LD, Serrano J et al (2024) Indomethacin with or without prophylactic pancreatic stent placement to prevent pancreatitis after ERCP: a randomised non-inferiority trial. Lancet 403(10425):450\u2013458. https:\/\/doi.org\/10.1016\/S0140-6736(23)02356-5","journal-title":"Lancet"},{"issue":"2","key":"11449_CR22","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.gie.2022.10.005","volume":"97","author":"JL Buxbaum","year":"2023","unstructured":"Buxbaum JL, Freeman M, Amateau SK et al (2023) American Society for Gastrointestinal Endoscopy guideline on post-ERCP pancreatitis prevention strategies: summary and recommendations. Gastrointest Endosc 97(2):153\u2013162. https:\/\/doi.org\/10.1016\/j.gie.2022.10.005","journal-title":"Gastrointest Endosc"},{"issue":"1","key":"11449_CR23","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/J.HBPD.2018.01.002","volume":"17","author":"M Chen","year":"2018","unstructured":"Chen M, Wang L, Wang Y et al. (2018) Risk factor analysis of post-ERCP cholangitis: a single-center experience. Hepatobiliary Pancreat Dis Int 17(1):55\u201358. https:\/\/doi.org\/10.1016\/J.HBPD.2018.01.002","journal-title":"Hepatobiliary Pancreat Dis Int"},{"issue":"7","key":"11449_CR24","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1111\/jgh.14954","volume":"35","author":"MX Xia","year":"2020","unstructured":"Xia MX, Wang SP, Wu J et al (2020) The risk of acute cholangitis after endoscopic stenting for malignant hilar strictures: a large comprehensive study. J Gastroenterol Hepatol (Australia) 35(7):1150\u20131157. https:\/\/doi.org\/10.1111\/jgh.14954","journal-title":"J Gastroenterol Hepatol (Australia)"},{"key":"11449_CR25","doi-asserted-by":"publisher","unstructured":"Lubbe J, Sandblom G, Arnelo U, Jonas E, Enochsson L (2021) Endoscopic stenting for malignant biliary obstruction: results of a nationwide experience. Clin Endosc. Published online May 31, 2021. https:\/\/doi.org\/10.5946\/ce.2021.016","DOI":"10.5946\/ce.2021.016"},{"issue":"1","key":"11449_CR26","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.gie.2008.10.039","volume":"70","author":"PB Cotton","year":"2009","unstructured":"Cotton PB, Garrow DA, Gallagher J, Romagnuolo J (2009) Risk factors for complications after ERCP: a multivariate analysis of 11,497 procedures over 12 years. Gastrointest Endosc 70(1):80\u201388. https:\/\/doi.org\/10.1016\/j.gie.2008.10.039","journal-title":"Gastrointest Endosc"},{"key":"11449_CR27","doi-asserted-by":"publisher","unstructured":"Kwak N, Yeoun D, Arroyo-Mercado F, Mubarak G, Cheung D, Vignesh S (2020) Outcomes and risk factors for ERCP-related complications in a predominantly black urban population. BMJ Open Gastroenterol 7(1). https:\/\/doi.org\/10.1136\/bmjgast-2020-000462","DOI":"10.1136\/bmjgast-2020-000462"},{"key":"11449_CR28","doi-asserted-by":"publisher","unstructured":"Teles de Campos S, Papaefthymiou A, Florou T et al (2023) Impact of center and endoscopist ERCP volume on ERCP outcomes: a systematic review and meta-analysis. Gastrointest Endosc 98(3):306\u2013315.e14. https:\/\/doi.org\/10.1016\/j.gie.2023.05.045","DOI":"10.1016\/j.gie.2023.05.045"},{"issue":"12","key":"11449_CR29","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1016\/J.CGH.2017.06.002","volume":"15","author":"RN Keswani","year":"2017","unstructured":"Keswani RN, Qumseya BJ, O\u2019Dwyer LC, Wani S (2017) Association between endoscopist and center endoscopic retrograde cholangiopancreatography volume with procedure success and adverse outcomes: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 15(12):1866-1875.e3. https:\/\/doi.org\/10.1016\/J.CGH.2017.06.002","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"11449_CR30","doi-asserted-by":"publisher","first-page":"257","DOI":"10.5009\/gnl18537","volume":"14","author":"HJ Lee","year":"2020","unstructured":"Lee HJ, Cho CM, Heo J et al (2020) Impact of hospital volume and the experience of endoscopist on adverse events related to endoscopic retrograde cholangiopancreatography: a prospective observational study. Gut Liver 14(2):257\u2013264. https:\/\/doi.org\/10.5009\/gnl18537","journal-title":"Gut Liver"},{"issue":"6","key":"11449_CR31","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1055\/s-0034-1391231","volume":"101","author":"VE Ekkelenkamp","year":"2015","unstructured":"Ekkelenkamp VE, De Man RA, Ter Borg F et al (2015) Prospective evaluation of ERCP performance: results of a nationwide quality registry. Endoscopy 101(6):503\u2013507. https:\/\/doi.org\/10.1055\/s-0034-1391231","journal-title":"Endoscopy"},{"issue":"9","key":"11449_CR32","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1055\/a-0659-9864","volume":"50","author":"JM Dumonceau","year":"2018","unstructured":"Dumonceau JM, Tringali A, Papanikolaou IS et al (2018) Endoscopic biliary stenting: indications, choice of stents, and results: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline\u2014Updated October 2017. Endoscopy 50(9):910\u2013930. https:\/\/doi.org\/10.1055\/a-0659-9864","journal-title":"Endoscopy"},{"issue":"7","key":"11449_CR33","doi-asserted-by":"publisher","first-page":"5339","DOI":"10.1007\/s00464-021-08915-y","volume":"36","author":"EL Syr\u00e9n","year":"2022","unstructured":"Syr\u00e9n EL, Sandblom G, Enochsson L et al (2022) Outcome of ERCP related to case-volume. Surg Endosc 36(7):5339\u20135347. https:\/\/doi.org\/10.1007\/s00464-021-08915-y","journal-title":"Surg Endosc"},{"key":"11449_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2019.11.005","author":"PR Harvey","year":"2020","unstructured":"Harvey PR, Baldwin S, Mytton J et al (2020) Higher volume providers are associated with improved outcomes following ERCP for the palliation of malignant biliary obstruction. Published online. https:\/\/doi.org\/10.1016\/j.eclinm.2019.11.005","journal-title":"Published online"},{"key":"11449_CR35","doi-asserted-by":"publisher","unstructured":"On W, Saleem MA, Hegade VS, Huggett MT, Paranandi B, Everett SM (2022) Factors predicting 30-day mortality after ERCP in patients with inoperable malignant hilar biliary obstruction: A single tertiary referral centre experience and systematic review. BMJ Open Gastroenterol 9(1). https:\/\/doi.org\/10.1136\/bmjgast-2022-000878","DOI":"10.1136\/bmjgast-2022-000878"}],"container-title":["Surgical Endoscopy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00464-024-11449-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00464-024-11449-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00464-024-11449-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T19:16:16Z","timestamp":1738696576000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00464-024-11449-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,13]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["11449"],"URL":"https:\/\/doi.org\/10.1007\/s00464-024-11449-8","relation":{},"ISSN":["0930-2794","1432-2218"],"issn-type":[{"value":"0930-2794","type":"print"},{"value":"1432-2218","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,13]]},"assertion":[{"value":"6 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None of the authors have any potential conflicts of interest to report. Dr Anna Forslund attended the ILCA 2022 Annual Conference on behalf of Roche AB. Dr Erik Haraldsson is a GallRiks regulatory board member. Dr Erik Holmberg, Dr Peter Naredi and Dr Magnus Rizell have no conflicts of interests or financial ties to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}